Longeveron (LGVN) is down 58% in pre-market trading Thursday, with shares last seen at $2.75, after the company's experimental cell therapy failed a pivotal clinical trial for a rare infant heart condition.
What Happened
Longeveron announced late Tuesday that its ELPIS II Phase 2b trial evaluating laromostoce for the treatment of hypoplastic left heart syndrome (HLHS) did not meet the primary endpoint. HLHS is a severe congenital heart defect in which the left side of the heart is critically underdeveloped, primarily affecting infants.
The company said it is now exploring strategic options following the failed trial, according to Reuters.
Why It Matters
Laromostoce, also known as LOMECEL-B, was Longeveron's lead clinical asset and had received considerable attention after a constructive Type C meeting with the FDA earlier in 2026. The therapy had shown promise in earlier trial phases, making the late-stage failure particularly unexpected.
Prior to Tuesday's announcement, the stock had already declined roughly 3.8% during regular trading hours Wednesday, closing at $6.60. The after-hours announcement triggered the sharp pre-market selloff seen Thursday.
Company Background
Longeveron is a Miami-based clinical stage biotechnology company with approximately 25 employees. Beyond HLHS, the company has been developing cell-based therapies for aging-related conditions, Alzheimer's disease, and acute respiratory distress syndrome.
Key Takeaways
- LGVN fell 58% in pre-market Thursday to $2.75
- The ELPIS II trial for laromostoce in HLHS failed to meet its primary endpoint
- Longeveron said it is now exploring strategic options
- The stock has shed roughly 80% of its value over the past year, according to available data
- Trading volume in the pre-market session reached 35,352 shares
The company's next steps remain unclear as it evaluates its pipeline following this setback. Investors and analysts will likely seek more details on the strategic review process during any forthcoming communications from management.